The OncoAlert🚨 Lung faculty’s TOP 10 abstracts In Thoracic🫁 Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior #LungCancer experts across #NSCLC & #SCLC . A snapshot of what will shape LUNG oncology at #ASCO26 👇 🔹 HARMONI-6 — Ivonescimab + chemo vs tislelizumab + chemo in sqNSCLC (OS, Ph3) 🔹 LIBRETTO-432 — Adjuvant selpercatinib in RET+ NSCLC (EFS, Ph3) 🔹 WU-KONG28 — Sunvozertinib vs chemo in EGFR Ex20ins NSCLC (Ph3) 🔹 OPTITROP-LUNGO5 — Sac-TMT + pembrolizumab in PD-L1+ NSCLC (Ph3) 🔹 TRITON — Tremelimumab/durvalumab/chemo in STK11/KEAP1/KRAS-mut NSCLC 🔹 CROWN 7-year update — Lorlatinib vs crizotinib in ALK+ NSCLC 🔹 LORIN — Neoadjuvant lorlatinib in stage III ALK+ NSCLC 🔹 ACCELERET-LUNG — 1L pralsetinib in RET+ NSCLC 🔹 Silevertinib (BDTX-1535) — Non-classical EGFR-mut NSCLC 🔹 Concurrent CRT + durvalumab in ES-SCLC (Phase III) Leads @HHorinouchi @UOzkerim @WeOncologists Senior Faculty @GlopesMd @StephenVLiu @peters_solange @CharuAggarwalMD @MartinReck2 @christine_lovly Participating AF @DrMirallas Pinging faculty @bmassutis @UmbertoMalapel1 @jillfeldman4 @bensolomon1 @VanitaNoronha @DrSanjayPopat @DrJNaidoo @Latinamd @JulienMazieres @TerriConneran @BRicciutiMD

The OncoAlert🚨 GU faculty’s TOP 10 abstracts In GU Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior GU cancer experts across #ProstateCancer #KidneyCancer #BladderCancer . A snapshot of what will shape GU oncology at #ASCO26 👇 1️⃣ LBA5007 — TALAPRO-3 Talazoparib + enzalutamide vs placebo + enzalutamide in mCSPC with HRR alterations 2️⃣ LBA1 — PROTEUS Perioperative apalutamide + ADT vs ADT in high-risk localized/locally advanced prostate cancer (final Phase 3) 3️⃣ 5001 — ENZAMET genomic analysis Decipher >0.85 to identify benefit from adding docetaxel to ADT + enzalutamide 4️⃣ LBA4511 — KEYNOTE-564 ctDNA ctDNA dynamics in RCC treated with adjuvant pembrolizumab vs placebo 5️⃣ 4502 — RAMPART Durvalumab vs active monitoring after resection in RCC (Phase 3 RCT) 6️⃣ 4500 — RADICAL (A031801) Radium-223 + cabozantinib in RCC with bone metastases 7️⃣ 4507 — EV-302 long-term follow-up Enfortumab vedotin + pembrolizumab vs chemotherapy in 1L LA/mUC 8️⃣ 4513 — AMBASSADOR (A031501) HRQoL with adjuvant pembrolizumab vs observation in high-risk MIBC 9️⃣ 4503 — SAKK 06/19 Perioperative intravesical rBCG + chemo-IO strategy in MIBC (primary analysis) 🔟 4510 — KEYNOTE-905 HRQoL with perioperative enfortumab vedotin + pembrolizumab in cisplatin-ineligible MIBC Leads @nataliagandur @scocmem @AmandaNizamMD @WeOncologists Senior Faculty @montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @Silke_Gillessen @tompowles1 @AndreaNecchi @cdanicas @AOmlin Pinging @crisbergerot @HHammersMD @ravikanesvaran @sonpavde @drenriquegrande @scserendipity1 @EfstathiouEleni @BraunMDPhD @brian_rini

🚨 The OncoAlert #BreastCancer faculty’s TOP 10 abstracts for #ASCO26 — selected by our leads and finalized through a Delphi voting process with senior breast cancer experts. 1️⃣ 500 — OPTIMA Test-directed chemotherapy in high-risk ER+/HER2- early BC 2️⃣ LBA1006 — PERSEVERA BC Giredestrant + palbociclib vs letrozole + palbociclib in 1L ER+/HER2- LA/MBC 3️⃣ 507 — KEYNOTE-522 final analysis Perioperative pembrolizumab in high-risk early TNBC 4️⃣ LBA1007 — SERENA-6 1L camizestrant for emergent ESR1 mutations — final PFS2 5️⃣ 502 — LIDERA BC Giredestrant in ER+/HER2- early BC by menopausal status 6️⃣ LBA1000 — ASCENT-04 SG + pembrolizumab vs chemo + pembrolizumab in 1L PD-L1+ mTNBC 7️⃣ 501 — NATALEE biomarker analysis Baseline gene expression and adjuvant ribociclib benefit 8️⃣ LBA503 — SENOMAC Omission of axillary dissection: OS + arm morbidity 9️⃣ 1001 — ASCENT-03 SG vs chemotherapy in 1L mTNBC — PFS2 🔟 LBA1003 Izalontamab brengitecan vs physician’s choice chemo in metastatic TNBC Leads🚨 @ElisaAgostinett @to_be_elizabeth @WeOncologists Senior Faculty @ErikaHamilton9 @E_de_Azambuja @matteolambe @DrSGraff @hoperugo @BianchiniGP Dr. Bidard @Icro_Meattini Participating AF @Lucarecco @GaiaGriguolo Ping Faculty @aftimosp @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @kevinpunie @nicolobattisti @raalbany @teamoncology @stolaney1 @LoiSher @SirohiBhawna @chemobrainfog @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @paspears88 @MammaMiaMagazin @itrisabel